PT  - JOURNAL ARTICLE
AU  - DeMaio, Andrew
AU  - Sterman, Daniel
TI  - Bronchoscopic intratumoural therapies for non-small cell lung cancer
AID  - 10.1183/16000617.0028-2020
DP  - 2020 Jun 30
TA  - European Respiratory Review
PG  - 200028
VI  - 29
IP  - 156
4099  - http://err.ersjournals.com/content/29/156/200028.short
4100  - http://err.ersjournals.com/content/29/156/200028.full
SO  - EUROPEAN RESPIRATORY REVIEW2020 Jun 30; 29
AB  - The past decade has brought remarkable improvements in the treatment of non-small cell lung cancer (NSCLC) with novel therapies, such as immune checkpoint inhibitors, although response rates remain suboptimal. Direct intratumoural injection of therapeutic agents via bronchoscopic approaches poses the unique ability to directly target the tumour microenvironment and offers several theoretical advantages over systemic delivery including decreased toxicity. Increases in understanding of the tumour microenvironment and cancer immunology have identified many potential options for intratumoural therapy, especially combination immunotherapies. Herein, we review advances in the development of novel bronchoscopic treatments for NSCLC over the past decade with a focus on the potential of intratumoural immunotherapy alone or in combination with systemic treatments.Bronchoscopic intratumoural injection of novel therapies holds remarkable potential for targeted treatment of non-small cell lung cancer with a reduced risk of toxicities https://bit.ly/36xraX7